Stephen E. Ammann
15Patents
2h-index
38Co-inventors
46Inventor score
Filing activity: May 24, 2017 → Jun 14, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US11702404B2 | GLP-1R modulating compounds | Chemistry; Metallurgy | 5 | Active |
| US10875866B2 | Pyrrolo[1,2-B]pyridazine derivatives | Emerging Cross-Sectional Technologies | 3 | Active |
| US11046686B2 | Thiadiazole IRAK4 compounds | Emerging Cross-Sectional Technologies | 2 | Active |
| US11535622B2 | Pyrrolo[1,2-b] pyridazine derivatives | Emerging Cross-Sectional Technologies | 1 | Active |
| US12091420B2 | SARS-COV2 main protease inhibitors | Chemistry; Metallurgy | 1 | Active |
| US11702414B2 | Thiadiazole IRAK4 inhibitors | Emerging Cross-Sectional Technologies | 1 | Active |
| US11572362B2 | Pyrrolo[1,2-b]pyridazine derivatives | Emerging Cross-Sectional Technologies | 0 | Active |
| US12121511B2 | GLP-1R modulating compounds | Chemistry; Metallurgy | 0 | Active |
| US10266503B1 | Sulfoxide ligand metal catalyzed oxidation of olefins | Chemistry; Metallurgy | 0 | Active |
| US11053250B2 | Pyrrolo[1,2-b]pyridazine derivatives | Emerging Cross-Sectional Technologies | 0 | Active |
| US12070455B2 | Thienopyrrole compounds | Emerging Cross-Sectional Technologies | 0 | Active |
| US12410183B2 | Sars-cov2 main protease inhibitors | Chemistry; Metallurgy | 0 | Active |
| US12060351B2 | Thiadiazole IRAK4 inhibitors | Emerging Cross-Sectional Technologies | 0 | Active |
| US11661431B2 | Thienopyrrole compounds | Chemistry; Metallurgy | 0 | Active |
| US12415808B2 | Pyrrolo[1,2-b]pyridazine derivatives | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.